Johnson & Johnson (JNJ) Given Consensus Rating of “Hold” by Analysts
Shares of Johnson & Johnson (NYSE:JNJ) have earned an average recommendation of “Hold” from the twenty-four research firms that are covering the firm. Two investment analysts have rated the stock with a sell rating, eleven have assigned a hold rating and eleven have assigned a buy rating to the company. The average twelve-month price objective among brokers that have issued ratings on the stock in the last year is $119.60.
Several research analysts recently weighed in on JNJ shares. Goldman Sachs Group Inc. set a $121.00 target price on Johnson & Johnson and gave the company a “neutral” rating in a research note on Monday, June 13th. Jefferies Group reaffirmed a “hold” rating and set a $109.00 target price (up previously from $108.00) on shares of Johnson & Johnson in a research note on Tuesday, June 14th. Barclays PLC reaffirmed an “overweight” rating and set a $125.00 target price (up previously from $120.00) on shares of Johnson & Johnson in a research note on Sunday, July 10th. Wells Fargo & Co. reaffirmed a “buy” rating on shares of Johnson & Johnson in a research note on Monday, July 11th. Finally, Royal Bank Of Canada raised their target price on Johnson & Johnson from $125.00 to $133.00 and gave the company an “outperform” rating in a research note on Wednesday, July 20th.
Johnson & Johnson (NYSE:JNJ) traded down 1.77% on Tuesday, hitting $117.68. 2,667,564 shares of the stock were exchanged. The company’s 50-day moving average is $118.85 and its 200-day moving average is $117.29. Johnson & Johnson has a 52 week low of $94.12 and a 52 week high of $126.07. The company has a market cap of $321.96 billion, a PE ratio of 21.93 and a beta of 0.62.
Johnson & Johnson (NYSE:JNJ) last issued its quarterly earnings results on Tuesday, July 19th. The company reported $1.74 EPS for the quarter, beating analysts’ consensus estimates of $1.68 by $0.06. The company had revenue of $18.50 billion for the quarter, compared to analyst estimates of $17.98 billion. Johnson & Johnson had a return on equity of 24.70% and a net margin of 20.97%. On average, analysts predict that Johnson & Johnson will post $6.69 earnings per share for the current year.
In other Johnson & Johnson news, CAO Ronald A. Kapusta sold 2,935 shares of the firm’s stock in a transaction that occurred on Friday, July 22nd. The stock was sold at an average price of $125.01, for a total value of $366,904.35. Following the sale, the chief accounting officer now owns 28,660 shares of the company’s stock, valued at approximately $3,582,786.60. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, VP Dominic J. Caruso sold 41,146 shares of the firm’s stock in a transaction that occurred on Tuesday, July 26th. The shares were sold at an average price of $125.01, for a total value of $5,143,661.46. Following the completion of the sale, the vice president now directly owns 157,819 shares in the company, valued at approximately $19,728,953.19. The disclosure for this sale can be found here. 0.11% of the stock is owned by corporate insiders.
A number of hedge funds have recently added to or reduced their stakes in the stock. Vanguard Group Inc. raised its stake in Johnson & Johnson by 2.2% in the second quarter. Vanguard Group Inc. now owns 184,512,652 shares of the company’s stock worth $22,381,384,000 after buying an additional 3,924,090 shares during the period. BlackRock Institutional Trust Company N.A. raised its stake in Johnson & Johnson by 0.5% in the second quarter. BlackRock Institutional Trust Company N.A. now owns 73,876,243 shares of the company’s stock worth $8,961,188,000 after buying an additional 345,527 shares during the period. BlackRock Fund Advisors raised its stake in Johnson & Johnson by 5.5% in the second quarter. BlackRock Fund Advisors now owns 42,089,045 shares of the company’s stock worth $5,105,401,000 after buying an additional 2,192,319 shares during the period. Massachusetts Financial Services Co. MA raised its stake in Johnson & Johnson by 1.0% in the second quarter. Massachusetts Financial Services Co. MA now owns 28,267,979 shares of the company’s stock worth $3,428,905,000 after buying an additional 283,866 shares during the period. Finally, BlackRock Group LTD raised its stake in Johnson & Johnson by 1.2% in the second quarter. BlackRock Group LTD now owns 25,315,774 shares of the company’s stock worth $3,070,804,000 after buying an additional 289,995 shares during the period. 65.32% of the stock is currently owned by hedge funds and other institutional investors.
About Johnson & Johnson
Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. The Company’s segments include Consumer, Pharmaceutical and Medical Devices. The Consumer segment includes a range of products used in the baby care, oral care, skin care, over-the-counter pharmaceutical, women’s health and wound care markets.
Receive News & Stock Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related stocks with our FREE daily email newsletter.